13
Participants
Start Date
March 16, 2017
Primary Completion Date
February 25, 2019
Study Completion Date
June 23, 2020
Interleukin-2
600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
Nivolumab
Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
Ohio State University, Columbus
University Hospitals Seidman Cancer Center, Cleveland
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Minnesota, Minneapolis
University of Michigan Rogel Cancer Center
OTHER